<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37085329</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>100</Volume><Issue>23</Issue><PubDate><Year>2023</Year><Month>Jun</Month><Day>06</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Development and Evaluation of a Simulation-Based Algorithm to Optimize the Planning of Interim Analyses for Clinical Trials in ALS.</ArticleTitle><Pagination><StartPage>e2398</StartPage><EndPage>e2408</EndPage><MedlinePgn>e2398-e2408</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000207306</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVES">Late-phase clinical trials for neurodegenerative diseases have a low probability of success. In this study, we introduce an algorithm that optimizes the planning of interim analyses for clinical trials in amyotrophic lateral sclerosis (ALS) to better use the time and resources available and minimize the exposure of patients to ineffective or harmful drugs.</AbstractText><AbstractText Label="METHODS">A simulation-based algorithm was developed to determine the optimal interim analysis scheme by integrating prior knowledge about the success rate of ALS clinical trials with drug-specific information obtained in early-phase studies. Interim analysis schemes were optimized by varying the number and timing of interim analyses, together with their decision rules about when to stop a trial. The algorithm was applied retrospectively to 3 clinical trials that investigated the efficacy of diaphragm pacing or ceftriaxone on survival in patients with ALS. Outcomes were additionally compared with conventional interim designs.</AbstractText><AbstractText Label="RESULTS">We evaluated 183-1,351 unique interim analysis schemes for each trial. Application of the optimal designs correctly established lack of efficacy, would have concluded all studies 1.2-19.4 months earlier (reduction of 4.6%-57.7% in trial duration), and could have reduced the number of randomized patients by 1.7%-58.1%. By means of simulation, we illustrate the efficiency for other treatment scenarios. The optimized interim analysis schemes outperformed conventional interim designs in most scenarios.</AbstractText><AbstractText Label="DISCUSSION">Our algorithm uses prior knowledge to determine the uncertainty of the expected treatment effect in ALS clinical trials and optimizes the planning of interim analyses. Improving futility monitoring in ALS could minimize the exposure of patients to ineffective or harmful treatments and result in significant ethical and efficiency gains.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van Unnik</LastName><ForeName>Jordi W J</ForeName><Initials>JWJ</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (J.W.J.v.U., L.H.v.d.B., R.P.A.v.E.), UMC Utrecht Brain Center, and Biostatistics &amp; Research Support (S.N., M.J.C.E., R.P.A.v.E.), Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, the Netherlands; Sorbonne Universit&#xe9; (J.G.-B., C.M.-P., T.S.), INSERM, UMRS1158 Neurophysiologie Respiratoire Exp&#xe9;rimentale et Clinique, AP-HP, Groupe Hospitalier Universitaire APHP-Sorbonne Universit&#xe9;, Site Piti&#xe9;-Salp&#xea;tri&#xe8;re, D&#xe9;partement R3S; APHP (G.B.), Groupe Hospitalier Paris 6, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, D&#xe9;partement de Neurologie, Centre R&#xe9;f&#xe9;rent SLA, France; Department of Neurology (M.E.C.), Massachusetts General Hospital, Boston; and Sheffield Institute for Translational Neuroscience (C.J.M.), University of Sheffield, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nikolakopoulos</LastName><ForeName>Stavros</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (J.W.J.v.U., L.H.v.d.B., R.P.A.v.E.), UMC Utrecht Brain Center, and Biostatistics &amp; Research Support (S.N., M.J.C.E., R.P.A.v.E.), Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, the Netherlands; Sorbonne Universit&#xe9; (J.G.-B., C.M.-P., T.S.), INSERM, UMRS1158 Neurophysiologie Respiratoire Exp&#xe9;rimentale et Clinique, AP-HP, Groupe Hospitalier Universitaire APHP-Sorbonne Universit&#xe9;, Site Piti&#xe9;-Salp&#xea;tri&#xe8;re, D&#xe9;partement R3S; APHP (G.B.), Groupe Hospitalier Paris 6, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, D&#xe9;partement de Neurologie, Centre R&#xe9;f&#xe9;rent SLA, France; Department of Neurology (M.E.C.), Massachusetts General Hospital, Boston; and Sheffield Institute for Translational Neuroscience (C.J.M.), University of Sheffield, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eijkemans</LastName><ForeName>Marinus J C</ForeName><Initials>MJC</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (J.W.J.v.U., L.H.v.d.B., R.P.A.v.E.), UMC Utrecht Brain Center, and Biostatistics &amp; Research Support (S.N., M.J.C.E., R.P.A.v.E.), Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, the Netherlands; Sorbonne Universit&#xe9; (J.G.-B., C.M.-P., T.S.), INSERM, UMRS1158 Neurophysiologie Respiratoire Exp&#xe9;rimentale et Clinique, AP-HP, Groupe Hospitalier Universitaire APHP-Sorbonne Universit&#xe9;, Site Piti&#xe9;-Salp&#xea;tri&#xe8;re, D&#xe9;partement R3S; APHP (G.B.), Groupe Hospitalier Paris 6, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, D&#xe9;partement de Neurologie, Centre R&#xe9;f&#xe9;rent SLA, France; Department of Neurology (M.E.C.), Massachusetts General Hospital, Boston; and Sheffield Institute for Translational Neuroscience (C.J.M.), University of Sheffield, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonzalez-Bermejo</LastName><ForeName>J&#xe9;sus</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (J.W.J.v.U., L.H.v.d.B., R.P.A.v.E.), UMC Utrecht Brain Center, and Biostatistics &amp; Research Support (S.N., M.J.C.E., R.P.A.v.E.), Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, the Netherlands; Sorbonne Universit&#xe9; (J.G.-B., C.M.-P., T.S.), INSERM, UMRS1158 Neurophysiologie Respiratoire Exp&#xe9;rimentale et Clinique, AP-HP, Groupe Hospitalier Universitaire APHP-Sorbonne Universit&#xe9;, Site Piti&#xe9;-Salp&#xea;tri&#xe8;re, D&#xe9;partement R3S; APHP (G.B.), Groupe Hospitalier Paris 6, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, D&#xe9;partement de Neurologie, Centre R&#xe9;f&#xe9;rent SLA, France; Department of Neurology (M.E.C.), Massachusetts General Hospital, Boston; and Sheffield Institute for Translational Neuroscience (C.J.M.), University of Sheffield, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruneteau</LastName><ForeName>Gaelle</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (J.W.J.v.U., L.H.v.d.B., R.P.A.v.E.), UMC Utrecht Brain Center, and Biostatistics &amp; Research Support (S.N., M.J.C.E., R.P.A.v.E.), Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, the Netherlands; Sorbonne Universit&#xe9; (J.G.-B., C.M.-P., T.S.), INSERM, UMRS1158 Neurophysiologie Respiratoire Exp&#xe9;rimentale et Clinique, AP-HP, Groupe Hospitalier Universitaire APHP-Sorbonne Universit&#xe9;, Site Piti&#xe9;-Salp&#xea;tri&#xe8;re, D&#xe9;partement R3S; APHP (G.B.), Groupe Hospitalier Paris 6, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, D&#xe9;partement de Neurologie, Centre R&#xe9;f&#xe9;rent SLA, France; Department of Neurology (M.E.C.), Massachusetts General Hospital, Boston; and Sheffield Institute for Translational Neuroscience (C.J.M.), University of Sheffield, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morelot-Panzini</LastName><ForeName>Capucine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (J.W.J.v.U., L.H.v.d.B., R.P.A.v.E.), UMC Utrecht Brain Center, and Biostatistics &amp; Research Support (S.N., M.J.C.E., R.P.A.v.E.), Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, the Netherlands; Sorbonne Universit&#xe9; (J.G.-B., C.M.-P., T.S.), INSERM, UMRS1158 Neurophysiologie Respiratoire Exp&#xe9;rimentale et Clinique, AP-HP, Groupe Hospitalier Universitaire APHP-Sorbonne Universit&#xe9;, Site Piti&#xe9;-Salp&#xea;tri&#xe8;re, D&#xe9;partement R3S; APHP (G.B.), Groupe Hospitalier Paris 6, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, D&#xe9;partement de Neurologie, Centre R&#xe9;f&#xe9;rent SLA, France; Department of Neurology (M.E.C.), Massachusetts General Hospital, Boston; and Sheffield Institute for Translational Neuroscience (C.J.M.), University of Sheffield, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Berg</LastName><ForeName>Leonard H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (J.W.J.v.U., L.H.v.d.B., R.P.A.v.E.), UMC Utrecht Brain Center, and Biostatistics &amp; Research Support (S.N., M.J.C.E., R.P.A.v.E.), Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, the Netherlands; Sorbonne Universit&#xe9; (J.G.-B., C.M.-P., T.S.), INSERM, UMRS1158 Neurophysiologie Respiratoire Exp&#xe9;rimentale et Clinique, AP-HP, Groupe Hospitalier Universitaire APHP-Sorbonne Universit&#xe9;, Site Piti&#xe9;-Salp&#xea;tri&#xe8;re, D&#xe9;partement R3S; APHP (G.B.), Groupe Hospitalier Paris 6, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, D&#xe9;partement de Neurologie, Centre R&#xe9;f&#xe9;rent SLA, France; Department of Neurology (M.E.C.), Massachusetts General Hospital, Boston; and Sheffield Institute for Translational Neuroscience (C.J.M.), University of Sheffield, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cudkowicz</LastName><ForeName>Merit E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (J.W.J.v.U., L.H.v.d.B., R.P.A.v.E.), UMC Utrecht Brain Center, and Biostatistics &amp; Research Support (S.N., M.J.C.E., R.P.A.v.E.), Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, the Netherlands; Sorbonne Universit&#xe9; (J.G.-B., C.M.-P., T.S.), INSERM, UMRS1158 Neurophysiologie Respiratoire Exp&#xe9;rimentale et Clinique, AP-HP, Groupe Hospitalier Universitaire APHP-Sorbonne Universit&#xe9;, Site Piti&#xe9;-Salp&#xea;tri&#xe8;re, D&#xe9;partement R3S; APHP (G.B.), Groupe Hospitalier Paris 6, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, D&#xe9;partement de Neurologie, Centre R&#xe9;f&#xe9;rent SLA, France; Department of Neurology (M.E.C.), Massachusetts General Hospital, Boston; and Sheffield Institute for Translational Neuroscience (C.J.M.), University of Sheffield, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDermott</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (J.W.J.v.U., L.H.v.d.B., R.P.A.v.E.), UMC Utrecht Brain Center, and Biostatistics &amp; Research Support (S.N., M.J.C.E., R.P.A.v.E.), Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, the Netherlands; Sorbonne Universit&#xe9; (J.G.-B., C.M.-P., T.S.), INSERM, UMRS1158 Neurophysiologie Respiratoire Exp&#xe9;rimentale et Clinique, AP-HP, Groupe Hospitalier Universitaire APHP-Sorbonne Universit&#xe9;, Site Piti&#xe9;-Salp&#xea;tri&#xe8;re, D&#xe9;partement R3S; APHP (G.B.), Groupe Hospitalier Paris 6, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, D&#xe9;partement de Neurologie, Centre R&#xe9;f&#xe9;rent SLA, France; Department of Neurology (M.E.C.), Massachusetts General Hospital, Boston; and Sheffield Institute for Translational Neuroscience (C.J.M.), University of Sheffield, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Similowski</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (J.W.J.v.U., L.H.v.d.B., R.P.A.v.E.), UMC Utrecht Brain Center, and Biostatistics &amp; Research Support (S.N., M.J.C.E., R.P.A.v.E.), Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, the Netherlands; Sorbonne Universit&#xe9; (J.G.-B., C.M.-P., T.S.), INSERM, UMRS1158 Neurophysiologie Respiratoire Exp&#xe9;rimentale et Clinique, AP-HP, Groupe Hospitalier Universitaire APHP-Sorbonne Universit&#xe9;, Site Piti&#xe9;-Salp&#xea;tri&#xe8;re, D&#xe9;partement R3S; APHP (G.B.), Groupe Hospitalier Paris 6, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, D&#xe9;partement de Neurologie, Centre R&#xe9;f&#xe9;rent SLA, France; Department of Neurology (M.E.C.), Massachusetts General Hospital, Boston; and Sheffield Institute for Translational Neuroscience (C.J.M.), University of Sheffield, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Eijk</LastName><ForeName>Ruben P A</ForeName><Initials>RPA</Initials><Identifier Source="ORCID">0000-0002-7132-5967</Identifier><AffiliationInfo><Affiliation>From the Department of Neurology (J.W.J.v.U., L.H.v.d.B., R.P.A.v.E.), UMC Utrecht Brain Center, and Biostatistics &amp; Research Support (S.N., M.J.C.E., R.P.A.v.E.), Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, the Netherlands; Sorbonne Universit&#xe9; (J.G.-B., C.M.-P., T.S.), INSERM, UMRS1158 Neurophysiologie Respiratoire Exp&#xe9;rimentale et Clinique, AP-HP, Groupe Hospitalier Universitaire APHP-Sorbonne Universit&#xe9;, Site Piti&#xe9;-Salp&#xea;tri&#xe8;re, D&#xe9;partement R3S; APHP (G.B.), Groupe Hospitalier Paris 6, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, D&#xe9;partement de Neurologie, Centre R&#xe9;f&#xe9;rent SLA, France; Department of Neurology (M.E.C.), Massachusetts General Hospital, Boston; and Sheffield Institute for Translational Neuroscience (C.J.M.), University of Sheffield, United Kingdom. r.p.a.vaneijk-2@umcutrecht.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>DiPALS, RespiStimALS and Ceftriaxone Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003198" MajorTopicYN="N">Computer Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018447" MajorTopicYN="N">Medical Futility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035501" MajorTopicYN="N">Uncertainty</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>J.W.J. van Unnik, S. Nikolakopoulos, M.J.C. Eijkemans, J. Gonzalez-Bermejo, G. Bruneteau, C. Morelot-Panzini, L.H. van den Berg, and M.E. Cudkowicz report no disclosures relevant to the manuscript. C.J. McDermott is supported by the NIHR Sheffield Biomedical Research Center and the NIHR Research Professorship Award. T. Similowski and R.P.A. van Eijk report no disclosures relevant to the manuscript. Go to Neurology.org/N for full disclosures.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>22</Day><Hour>10</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>21</Day><Hour>21</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37085329</ArticleId><ArticleId IdType="pmc">PMC10256133</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000207306</ArticleId><ArticleId IdType="pii">WNL.0000000000207306</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mitsumoto H, Brooks BR, Silani V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol. 2014;13(11):1127-1138. doi:10.1016/S1474-4422(14)70129-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70129-2</ArticleId><ArticleId IdType="pubmed">25316019</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov D, Mansfield C, Moussy A, Hermine O. ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment? Front Aging Neurosci. 2017;9:68. doi:10.3389/fnagi.2017.00068</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00068</ArticleId><ArticleId IdType="pmc">PMC5360725</ArticleId><ArticleId IdType="pubmed">28382000</ArticleId></ArticleIdList></Reference><Reference><Citation>Wobst HJ, Mack KL, Brown DG, Brandon NJ, Shorter J. The clinical trial landscape in amyotrophic lateral sclerosis: past, present, and future. Med Res Rev. 2020;40(4):1352-1384. doi:10.1002/med.21661</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21661</ArticleId><ArticleId IdType="pmc">PMC7417284</ArticleId><ArticleId IdType="pubmed">32043626</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacomblez L, Bensimon G, Meininger V, Leigh P, Guillet P. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet. 1996;347(9013):1425-1431. doi:10.1016/S0140-6736(96)91680-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(96)91680-3</ArticleId><ArticleId IdType="pubmed">8676624</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Aoki M, Tsuji S, et al. . Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(7):505-512. doi:10.1016/S1474-4422(17)30115-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, van den Berg LH. Edaravone: a new treatment for ALS on the horizon? Lancet Neurol. 2017;16(7):490-491. doi:10.1016/S1474-4422(17)30163-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30163-1</ArticleId><ArticleId IdType="pubmed">28522180</ArticleId></ArticleIdList></Reference><Reference><Citation>Meininger V, Asselain B, Guillet P, et al. . Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial. Neurology. 2006;66(1):88-92. doi:10.1212/01.WNL.0000191326.40772.62</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000191326.40772.62</ArticleId><ArticleId IdType="pubmed">16401852</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon PH, Moore DH, Miller RG, et al. . Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 2007;6(12):1045-1053. doi:10.1016/S1474-4422(07)70270-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(07)70270-3</ArticleId><ArticleId IdType="pubmed">17980667</ArticleId></ArticleIdList></Reference><Reference><Citation>Piepers S, Veldink JH, De Jong SW, et al. . Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis. Ann Neurol. 2009;66(2):227-234. doi:10.1002/ana.21620</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21620</ArticleId><ArticleId IdType="pubmed">19743466</ArticleId></ArticleIdList></Reference><Reference><Citation>McDermott CJ, Shaw PJ, Cooper CL, et al. . Safety and efficacy of diaphragm pacing in patients with respiratory insufficiency due to amyotrophic lateral sclerosis (DiPALS): a multicentre, open-label, randomised controlled trial. Lancet Neurol. 2015;14(9):883-892. doi:10.1016/S1474-4422(15)00152-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(15)00152-0</ArticleId><ArticleId IdType="pubmed">26234554</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Bermejo J, Mor&#xe9;lot-Panzini C, Tanguy ML, et al. . Early diaphragm pacing in patients with amyotrophic lateral sclerosis (RespiStimALS): a randomised controlled triple-blind trial. Lancet Neurol. 2016;15(12):1217-1227. doi:10.1016/S1474-4422(16)30233-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)30233-2</ArticleId><ArticleId IdType="pubmed">27751553</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, Nikolakopoulos S, Ferguson TA, Liu D, Eijkemans MJ, van den Berg LH. Increasing the efficiency of clinical trials in neurodegenerative disorders using group sequential trial designs. J Clin Epidemiol. 2018;98:80-88. doi:10.1016/j.jclinepi.2018.02.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2018.02.013</ArticleId><ArticleId IdType="pubmed">29486281</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong C, Stavrou M, Elliott E, et al. . Clinical trials in amyotrophic lateral sclerosis: a systematic review and perspective. Brain Commun. 2021;3(4):fcab242. doi:10.1093/BRAINCOMMS/FCAB242</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/BRAINCOMMS/FCAB242</ArticleId><ArticleId IdType="pmc">PMC8659356</ArticleId><ArticleId IdType="pubmed">34901853</ArticleId></ArticleIdList></Reference><Reference><Citation>Meurer WJ, Tolles J. Interim analyses during group sequential clinical trials. JAMA. 2021;326(15):1524-1525. doi:10.1001/JAMA.2021.10174</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/JAMA.2021.10174</ArticleId><ArticleId IdType="pubmed">34596661</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman LM, Furberg CD, DeMets D, et al. . Fundamentals of Clinical Trials. 5th ed. Springer; 2015.</Citation></Reference><Reference><Citation>Nikolakopoulos S, Roes KC, van der Tweel I. Sequential designs with small samples: evaluation and recommendations for normal responses. Stat Methods Med Res. 2018;27(4):1115-1127. doi:10.1177/0962280216653778</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0962280216653778</ArticleId><ArticleId IdType="pubmed">27342574</ArticleId></ArticleIdList></Reference><Reference><Citation>Pocock SJ. Group sequential methods in the design and analysis of clinical trials. Biometrika. 1977;64(2):191-199. doi:10.2307/2335684</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/2335684</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35(3):549-556. doi:10.2307/2530245</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/2530245</ArticleId><ArticleId IdType="pubmed">497341</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Hagan A, Stevens JW, Campbell MJ. Assurance in clinical trial design. Pharm Stat. 2005;4(3):187-201. doi:10.1002/pst.175</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pst.175</ArticleId></ArticleIdList></Reference><Reference><Citation>Tornese P, Lalli S, Cocco A, Albanese A. Review of disease-modifying drug trials in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2022;93(5):521-529. doi:10.1136/jnnp-2021-328470</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2021-328470</ArticleId><ArticleId IdType="pubmed">35228271</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, Titus S, Kearney M, et al. . Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13(11):1083-1091. doi:10.1016/S1474-4422(14)70222-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70222-4</ArticleId><ArticleId IdType="pmc">PMC4216315</ArticleId><ArticleId IdType="pubmed">25297012</ArticleId></ArticleIdList></Reference><Reference><Citation>US Food and Drug Administration. Summary of safety and probable benefit (SSPB). 2011. Accessed April 29, 2021. accessdata.fda.gov/cdrh_docs/pdf10/H100006b.pdf.</Citation></Reference><Reference><Citation>Van Eijk RPA, Nikolakopoulos S, Roes KCB, et al. . Critical design considerations for time-to-event endpoints in amyotrophic lateral sclerosis clinical trials. J Neurol Neurosurg Psychiatry. 2019;90(12):1331-1337. doi:10.1136/jnnp-2019-320998</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-320998</ArticleId><ArticleId IdType="pmc">PMC6902062</ArticleId><ArticleId IdType="pubmed">31292200</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian Approaches to Clinical Trials and Health-Care Evaluation. John Wiley &amp; Sons, Ltd.; 2004.</Citation></Reference><Reference><Citation>Berry JD, Shefner JM, Conwit R, et al. . Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis. PLoS One. 2013;8(4):e61177. doi:10.1371/JOURNAL.PONE.0061177</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/JOURNAL.PONE.0061177</ArticleId><ArticleId IdType="pmc">PMC3629222</ArticleId><ArticleId IdType="pubmed">23613806</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Eijk RPA, Eijkemans MJC, Ferguson TA, Nikolakopoulos S, Veldink JH, van den Berg LH. Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials. J Neurol Neurosurg Psychiatry. 2018;89(2):156-161. doi:10.1136/JNNP-2017-317077</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/JNNP-2017-317077</ArticleId><ArticleId IdType="pmc">PMC5800333</ArticleId><ArticleId IdType="pubmed">29084868</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, Nikolakopoulos S, Roes KCB, et al. . Innovating clinical trials for amyotrophic lateral sclerosis: challenging the established order. Neurology. 2021;97(11):528-536. doi:10.1212/WNL.0000000000012545</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000012545</ArticleId><ArticleId IdType="pmc">PMC8456357</ArticleId><ArticleId IdType="pubmed">34315786</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency. Reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design. 2007. Accessed April 20, 2021. ema.europa.eu/en/documents/scientific-guideline/reflection-paper-methodological-issues-confirmatory-clinical-trials-planned-adaptive-design_en.pdf.</Citation></Reference><Reference><Citation>US Food and Drug Administration. Adaptive Design Clinical Trials for Drugs and Biologics Guidance for Industry. 2019. Accessed May 6, 2021. fda.gov/regulatory-information/search-fda-guidance-documents/adaptive-design-clinical-trials-drugs-and-biologics-guidance-industry.</Citation></Reference><Reference><Citation>Pocock SJ. When to stop a clinical trial. BMJ. 1992;305(6847):235-240. doi:10.1136/BMJ.305.6847.235</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/BMJ.305.6847.235</ArticleId><ArticleId IdType="pmc">PMC1882707</ArticleId><ArticleId IdType="pubmed">1392832</ArticleId></ArticleIdList></Reference><Reference><Citation>Lachin JM, Foulkes MA. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics. 1986;42(3):507-519. doi:10.2307/2531201</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/2531201</ArticleId><ArticleId IdType="pubmed">3567285</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevely A, Dimairo M, Todd S, et al. . An investigation of the shortcomings of the CONSORT 2010 statement for the reporting of group sequential randomised controlled trials: a methodological systematic review. PLoS One. 2015;10(11):e0141104. doi:10.1371/journal.pone.0141104</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0141104</ArticleId><ArticleId IdType="pmc">PMC4631356</ArticleId><ArticleId IdType="pubmed">26528812</ArticleId></ArticleIdList></Reference><Reference><Citation>Jennison C, Turnbull BW. Group Sequential Methods with Applications to Clinical Trials. Chapman and Hall/CRC; 1999.</Citation></Reference><Reference><Citation>I AM ALS Clinical Trials Team. Patient-Centric Trial Design (PaCTD) Rating Criteria. Accessed April 15, 2022. iamals.org/patient-centric-trial-design-pactd-rating-criteria/.</Citation></Reference><Reference><Citation>Van Den Berg LH, Sorenson E, Gronseth G, et al. . Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. Neurology. 2019;92(14):e1610-e1623. doi:10.1212/WNL.0000000000007242</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007242</ArticleId><ArticleId IdType="pmc">PMC6448453</ArticleId><ArticleId IdType="pubmed">30850440</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimairo M, Julious SA, Todd S, Nicholl JP, Boote J. Cross-sector surveys assessing perceptions of key stakeholders towards barriers, concerns and facilitators to the appropriate use of adaptive designs in confirmatory trials. Trials. 2015;16(1):585. doi:10.1186/s13063-015-1119-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-015-1119-x</ArticleId><ArticleId IdType="pmc">PMC4690427</ArticleId><ArticleId IdType="pubmed">26700741</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen TT. Statistical issues and challenges in immuno-oncology. J Immunother Cancer. 2013;1:18. doi:10.1186/2051-1426-1-18</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2051-1426-1-18</ArticleId><ArticleId IdType="pmc">PMC4019889</ArticleId><ArticleId IdType="pubmed">24829754</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatt DL, Mehta C. Adaptive designs for clinical trials. N Engl J Med. 2016;375(1):65-74. doi:10.1056/NEJMRA1510061</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMRA1510061</ArticleId><ArticleId IdType="pubmed">27406349</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnett T, Mozgunov P, Pallmann P, Villar SS, Wheeler GM, Jaki T. Adding flexibility to clinical trial designs: an example-based guide to the practical use of adaptive designs. BMC Med. 2020;18(1):352. doi:10.1186/S12916-020-01808-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/S12916-020-01808-2</ArticleId><ArticleId IdType="pmc">PMC7677786</ArticleId><ArticleId IdType="pubmed">33208155</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, Hardiman O, Chio A, et al. . Amyotrophic lateral sclerosis. Lancet. 2017;390(10107):2084-2098. doi:10.1016/S0140-6736(17)31287-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Psioda MA, Ibrahim JG. Bayesian clinical trial design using historical data that inform the treatment effect. Biostatistics. 2019;20(3):400-415. doi:10.1093/biostatistics/kxy009</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biostatistics/kxy009</ArticleId><ArticleId IdType="pmc">PMC6587921</ArticleId><ArticleId IdType="pubmed">29547966</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X, Xu Y, Carlin BP. Optimizing interim analysis timing for Bayesian adaptive commensurate designs. Stat Med. 2020;39(4):424-437. doi:10.1002/SIM.8414</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/SIM.8414</ArticleId><ArticleId IdType="pubmed">31799737</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng HJ, Debray TPA, Visser AE, et al. . Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17(5):423-433. doi:10.1016/S1474-4422(18)30089-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30089-9</ArticleId><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, Westeneng HJ, Nikolakopoulos S, et al. . Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials. Neurology. 2019;92(5):e451-e460. doi:10.1212/WNL.0000000000006855</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006855</ArticleId><ArticleId IdType="pmc">PMC6369899</ArticleId><ArticleId IdType="pubmed">30626653</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Macklin EA, Hendrix S, et al. . Trial of sodium phenylbutyrate&#x2013;taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383(10):919-930. doi:10.1056/nejmoa1916945</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa1916945</ArticleId><ArticleId IdType="pmc">PMC9134321</ArticleId><ArticleId IdType="pubmed">32877582</ArticleId></ArticleIdList></Reference><Reference><Citation>Oki R, Izumi Y, Fujita K, et al. . Efficacy and safety of ultrahigh-dose methylcobalamin in early-stage amyotrophic lateral sclerosis: a randomized clinical trial. JAMA Neurol. 2022;79(6):575-583. doi:10.1001/JAMANEUROL.2022.0901</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/JAMANEUROL.2022.0901</ArticleId><ArticleId IdType="pmc">PMC9086935</ArticleId><ArticleId IdType="pubmed">35532908</ArticleId></ArticleIdList></Reference><Reference><Citation>Wason JMS, Brocklehurst P, Yap C. When to keep it simple: adaptive designs are not always useful. BMC Med. 2019;17(1):152. doi:10.1186/s12916-019-1391-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-019-1391-9</ArticleId><ArticleId IdType="pmc">PMC6676635</ArticleId><ArticleId IdType="pubmed">31370839</ArticleId></ArticleIdList></Reference><Reference><Citation>Baxi EG, Thompson T, Li J, et al. . Answer ALS, a large-scale resource for sporadic and familial ALS combining clinical and multi-omics data from induced pluripotent cell lines. Nat Neurosci. 2022;25(2):226-237. doi:10.1038/s41593-021-01006-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-021-01006-0</ArticleId><ArticleId IdType="pmc">PMC8825283</ArticleId><ArticleId IdType="pubmed">35115730</ArticleId></ArticleIdList></Reference><Reference><Citation>Atassi N, Berry J, Shui A, et al. . The PRO-ACT database: design, initial analyses, and predictive features. Neurology. 2014;83(19):1719-1725. doi:10.1212/WNL.0000000000000951</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000951</ArticleId><ArticleId IdType="pmc">PMC4239834</ArticleId><ArticleId IdType="pubmed">25298304</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>